uՏ`wuv̌Ɛт̃f[^łB




[ _@ ]


1. Kitakaze K., Mizutani Y., Sugiyama E., Tasaki C., Tsuji D., Maita N., Hirokawa T., Asanuma D., Kamiya M., Sato K., Setou M., Urano Y., Togawa T., Otaka A., Sakuraba H., Itoh K.: Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model. J. Clin. Invest., 126: 1691-1703, 2016.

2. Kitakaze K., Tasaki C., Tajima Y., Hirokawa T., Tsuji D., Sakuraba H., Itoh K.: Combined replacement effects of human modified β-hexosaminidase B and GM2 activator protein on GM2 gangliosidoses fibroblasts. Biochem. Biophys. Reports, 7: 157-163, 2016.

3. Kubo T., Ochi Y., Baba Y., Hirota T., Tanioka K., Yamasaki N., Yoshimitsu M., Higuchi K., Takenaka T., Nakajima K., Togawa T., Tsukimura T., Sano S., Tei C., Sakuraba H., Kitaoka H.: Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J. Cardiol., S0914-5087(16)30104-6, 2016.

4. Kosuga M., Mashima R., Hirakiyama A., Fuji N., Kumagai T., Seo JH., Nikaido M., Saito S., Ohno K., Sakuraba H., Okuyama T.: Molecular diagnosis of 65 families with mucopolysaccharidosis type II (Hunter syndrome) characterized by 16 novel mutations in the IDS gene: Genetic, pathological, and structural studies on iduronate-2-sulfatase. Mol. Genet. Metab., 118: 190-197, 2016.